Stocks News

LAST PRICE
754.8200
TODAY'S CHANGE (%)
Trending Up1.7900 (0.2377%)

Bid / Lots
750.0000/ 1
Ask / Lots
780.0000/ 1
Open / Previous Close
756.7200 / 753.0300
Day Range
Low 749.5150
High 762.1600
52 Week Range
Low 735.9548
High 1,211.1999
Volume
544,779
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: REGN
  
  Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
  LOS ANGELES--(BUSINESS WIRE)--November 27, 2024--
Nov 26, 2024
- ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Accesswire
  1:01PM ET on Tuesday Nov 26, 2024 by Accesswire
  Companies Mentioned: REGN
  NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws.
- ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
  1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws.
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
  BENSALEM, Pa.--(BUSINESS WIRE)--November 26, 2024--
Nov 25, 2024
- The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Monday Nov 25, 2024 by Dow Jones
  12:00PM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: REGN
  
  The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
  
  LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws.

Yesterday
- "LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 9 hours ago by PR Newswire
  9 hours ago by PR Newswire
  Companies Mentioned: BIIB
- "LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: BIIB
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: ICLR
Nov 26, 2024
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: ICLR
- Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating, from 7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires
  7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: IQV
Nov 25, 2024
- The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 12:00PM ET on Monday Nov 25, 2024 by Dow Jones
  12:00PM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: ICLR
- Levi & Korsinsky Reminds ICON Public Limited Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ICLR, from 7:33AM ET on Monday Nov 25, 2024 by Accesswire
  7:33AM ET on Monday Nov 25, 2024 by Accesswire
  Companies Mentioned: ICLR
- Levi & Korsinsky Reminds ICON Public Limited Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ICLR, from 7:33AM ET on Monday Nov 25, 2024 by Dow Jones
  7:33AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: ICLR
- Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: IQV
- Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: IQV

Regeneron Pharmaceuticals Inc
NASDAQ:REGNUnited States

Search Criteria

Yesterday

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 13 hours ago by Dow Jones

Nov 26, 2024

ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Accesswire

ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 25, 2024

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Monday Nov 25, 2024 by Dow Jones

Peers Headlines

Yesterday

"LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 9 hours ago by PR Newswire

"LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 9 hours ago by Dow Jones

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 13 hours ago by Dow Jones

Nov 26, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones

Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating, from 7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires

Nov 25, 2024

The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 12:00PM ET on Monday Nov 25, 2024 by Dow Jones

Levi & Korsinsky Reminds ICON Public Limited Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ICLR, from 7:33AM ET on Monday Nov 25, 2024 by Accesswire

Levi & Korsinsky Reminds ICON Public Limited Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ICLR, from 7:33AM ET on Monday Nov 25, 2024 by Dow Jones

Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires

Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires